HMMR and acute myeloid leukemia: On the contrary, a study by Schauwaert et al. concluded that RHAMM is a suboptimal target antigen for immunotherapy approaches in AML patients, due to an equal expression level of RHAMM in leukemic stem cells and hematopoietic stem cells from healthy controls indicating that an elimination of leukemic stem cells is unlikely to be achieved by RHAMM-directed immunotherapy [134].